# Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis

> **NCT03832738** · PHASE2 · COMPLETED · sponsor: **Akros Pharma Inc.** · enrollment: 152 (actual)

## Conditions studied

- Plaque Psoriasis
- Psoriasis
- Skin Diseases

## Interventions

- **DRUG:** JTE-451 Tablets
- **DRUG:** Placebo Tablets

## Key facts

- **NCT ID:** NCT03832738
- **Lead sponsor:** Akros Pharma Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-01-17
- **Primary completion:** 2020-03-13
- **Final completion:** 2020-03-13
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2021-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03832738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03832738, "Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-09-15 from https://api.ai-analytics.org/clinical/NCT03832738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*